The World Orphan Drug Congress will be going into its 6th year in November 2015. The Congress was one of the first events to bring together the full range of stakeholders and influencers in the orphan drug and rare disease sector, from the pharma and biotechs (GSK, Novartis, Celgene, Takeda) to patient advocates and representatives from payers. It continues to be a key meeting for the sector in pushing forward with strategy, advocacy and partnering within the rare disease space. This year’s congress will be continuing to cover the issues that affect the full audience, including pricing and reimbursement, commercialisation, and improving on collaboration, as well as researching the newest areas to ensure the focused content reflects the future of the sector. We are also going to be working hard to increase the numbers of representatives present from the HTA, payer and public health arenas, as it is so important to have their input throughout the discussions onsite. Additionally, we will be inviting more members of the patient advocacy community.The 2015 conference will provide you with:Track content to suit your day-to-day as well sessions addressing the key challenges impacting the whole sector.  There will be content specific to industry and market access, how to better work with patient groups, making clinical trials as efficient and effective as possible and using social media to improve communications with patients.Fantastic networking- with over 400 of your peers in one room, the conference guarantees invaluable networking opportunities.Patient alliance zone- patient advocacy groups can present and discuss the work they are doing in their communities and with industry, to raise awareness and build relationships.A solution Provider Exhibition. Don’t phone around tons of suppliers; visit 30+ focused exhibition stands on-site to find your perfect partner